We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop Molecular Diagnostics

By HospiMedica staff writers
Posted on 04 Jul 2002
A long-term strategic alliance to develop, manufacture, and market a broad range of in vitro molecular diagnostic products has been announced by Abbott Laboratories (Abbott Park, IL, USA) and Celera Diagnostics Group (Alameda, CA, USA), a joint venture between Abbott and Applied Biosystems Group (Foster City, CA, USA).

The alliance plans to develop and commercialize molecular diagnostic products for disease detection, monitoring, and therapy selection. More...
Diseases and chronic conditions to be targeted include cardiovascular and autoimmune diseases, central nervous system disorders, and cancer. Around 250 scientists and engineers from the two companies will initially be devoted to the program, which will encompass a large-scale discovery effort to identify new diagnostic markers. Celera will focus on genetic marker discovery, new marker validation, and assay development. Abbott will focus on product development, sales, and marketing. The two companies will share technologies, patents, profits, and expenditures.

"This will help accelerate our joint strategy to develop and market a broad menu of next-generation molecular diagnostic products focused on unmet diagnostic needs,” said Edward Michael, vice president, commercial operations, diagnostics, Abbott Laboratories.



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical-Grade Display
HL2316SHTB
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.